OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach
Introduction: There are limited data comparing long-term efficacy and safety of OPTIMA tacrolimus-eluting stent (TES) with Dual Antiplatelet Therapy (DAT) in daily practice. Therefore, we evaluated the safety and performance of OPTIMA TES with 2 or 6-month dual antiplatelet therapy in a 12-month fol...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2012-09-01
|
Series: | Journal of Cardiovascular and Thoracic Research |
Subjects: | |
Online Access: | http://dx.doi.org/ 10.5681/jcvtr.2012.020 |
id |
doaj-6b9a4b24a2e44fc6b8c511a848c54750 |
---|---|
record_format |
Article |
spelling |
doaj-6b9a4b24a2e44fc6b8c511a848c547502020-11-24T20:57:13ZengTabriz University of Medical SciencesJournal of Cardiovascular and Thoracic Research2008-51172008-68302012-09-01438184OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month ApproachNasser AslanabadiAhmad SeparhamReza BeheshtiSamad GhaffariBahram SohrabiIntroduction: There are limited data comparing long-term efficacy and safety of OPTIMA tacrolimus-eluting stent (TES) with Dual Antiplatelet Therapy (DAT) in daily practice. Therefore, we evaluated the safety and performance of OPTIMA TES with 2 or 6-month dual antiplatelet therapy in a 12-month follow up period. Methods: In a prospective, non-randomized single center registry in which 106 patients that underwent percutaneous coronary intervention with the OPTIMA TES between January 2010 and February 2011 were enrolled. After stenting, 62 patients received DAT for 2 months and the remainder for 6 months. Major Adverse Cardiac Events (MACE), stent thrombosis rate and target lesion revascularization (TLR) were evaluated in a 12-month follow-up period for 2-and 6-month DAT groups. Results: No cases with death, MI or stent thrombosis were observed within the 12-month follow-up period in either of the groups. TLR and MACE rates were higher in 6-month DAT group compared to 2-month group (6.8% vs. 3.2% respectively, P=0.001) which may be due to this group having more diffuse disease (23.60±5.69 vs. 20.88±5.14, P=0.018).Conclusions: OPTIMA tacrolimus-eluting stent is safe and efficient with short term DAT period. A randomized trial is needed for better evaluations of OPTIMA TES in daily clinical practice.http://dx.doi.org/ 10.5681/jcvtr.2012.020Tacrolimus- eluting StentPCIStent ThrombosisDual Antiplatelet Therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nasser Aslanabadi Ahmad Separham Reza Beheshti Samad Ghaffari Bahram Sohrabi |
spellingShingle |
Nasser Aslanabadi Ahmad Separham Reza Beheshti Samad Ghaffari Bahram Sohrabi OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach Journal of Cardiovascular and Thoracic Research Tacrolimus- eluting Stent PCI Stent Thrombosis Dual Antiplatelet Therapy |
author_facet |
Nasser Aslanabadi Ahmad Separham Reza Beheshti Samad Ghaffari Bahram Sohrabi |
author_sort |
Nasser Aslanabadi |
title |
OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach |
title_short |
OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach |
title_full |
OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach |
title_fullStr |
OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach |
title_full_unstemmed |
OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach |
title_sort |
optima tacrolimus-eluting stent: a twelve-month clinical follow up with two different periods of dual antiplatelet therapy; 2-monthvs. 6-month approach |
publisher |
Tabriz University of Medical Sciences |
series |
Journal of Cardiovascular and Thoracic Research |
issn |
2008-5117 2008-6830 |
publishDate |
2012-09-01 |
description |
Introduction: There are limited data comparing long-term efficacy and safety of OPTIMA tacrolimus-eluting stent (TES) with Dual Antiplatelet Therapy (DAT) in daily practice. Therefore, we evaluated the safety and performance of OPTIMA TES with 2 or 6-month dual antiplatelet therapy in a 12-month follow up period. Methods: In a prospective, non-randomized single center registry in which 106 patients that underwent percutaneous coronary intervention with the OPTIMA TES between January 2010 and February 2011 were enrolled. After stenting, 62 patients received DAT for 2 months and the remainder for 6 months. Major Adverse Cardiac Events (MACE), stent thrombosis rate and target lesion revascularization (TLR) were evaluated in a 12-month follow-up period for 2-and 6-month DAT groups. Results: No cases with death, MI or stent thrombosis were observed within the 12-month follow-up period in either of the groups. TLR and MACE rates were higher in 6-month DAT group compared to 2-month group (6.8% vs. 3.2% respectively, P=0.001) which may be due to this group having more diffuse disease (23.60±5.69 vs. 20.88±5.14, P=0.018).Conclusions: OPTIMA tacrolimus-eluting stent is safe and efficient with short term DAT period. A randomized trial is needed for better evaluations of OPTIMA TES in daily clinical practice. |
topic |
Tacrolimus- eluting Stent PCI Stent Thrombosis Dual Antiplatelet Therapy |
url |
http://dx.doi.org/ 10.5681/jcvtr.2012.020 |
work_keys_str_mv |
AT nasseraslanabadi optimatacrolimuselutingstentatwelvemonthclinicalfollowupwithtwodifferentperiodsofdualantiplatelettherapy2monthvs6monthapproach AT ahmadseparham optimatacrolimuselutingstentatwelvemonthclinicalfollowupwithtwodifferentperiodsofdualantiplatelettherapy2monthvs6monthapproach AT rezabeheshti optimatacrolimuselutingstentatwelvemonthclinicalfollowupwithtwodifferentperiodsofdualantiplatelettherapy2monthvs6monthapproach AT samadghaffari optimatacrolimuselutingstentatwelvemonthclinicalfollowupwithtwodifferentperiodsofdualantiplatelettherapy2monthvs6monthapproach AT bahramsohrabi optimatacrolimuselutingstentatwelvemonthclinicalfollowupwithtwodifferentperiodsofdualantiplatelettherapy2monthvs6monthapproach |
_version_ |
1716788408900124672 |